Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

MOUNTAIN VIEW, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable product to treat acute agitation. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"We are excited to be initiating our AZ-004 NDA plan with this first Phase 3 clinical trial," said Thomas B. King, Alexza President and CEO. "The results we have seen to date with AZ-004 have been promising and we look forward to enrolling the planned Phase 3 clinical trials as quickly as possible. This is a transitional year in our history as we move into the early commercial planning for the manufacturing, regulatory submissions, and potential sales and marketing of AZ-004."

AZ-004 Phase 3 Clinical Trial Design

The first AZ-004 Phase 3 clinical trial is designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, 5 and 10 mg. Patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status.

The primary endpoint for the study is the change from baseline in the PANSS (Positive and
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... As interest increases in developing novel biomarker ... the need to keep up with the pace of ... the first in a series titled “Better Methods for ... a range of technologies, introduces a novel method for ... proteins than either ELISA or traditional LCMS can achieve. ...
(Date:6/17/2013)... 17, 2013 Spirax Sarco has ... Steam News Magazine App. Readers can now subscribe to a ... Each issue is now fully downloadable to an iPad or ... have the opportunity to read all of its content at ... remains 100% faithful to the current digital edition with additional ...
(Date:6/14/2013)... time you see a fruit fly in your kitchen, ... impact on our progress in deciphering sensory biology and ... the human brain. , UC Santa Barbara researchers ... (MCDB) and the Neuroscience Research Institute (NRI) have been ... Drosophila (fruit flies). And they have made some ...
(Date:6/14/2013)... June 14, 2013 The OpenClinica ... Hotel, Boston, MA this year with Formedix CEO, Mark ... valuable sessions, offering attendees a deeper insight into the ... with partners, such as Formedix to develop innovative solutions. ... to learn all about OpenClinica, hear real-life case studies ...
Breaking Biology Technology:Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks 2Spirax Sarco Launches Steam News Magazine for iPad and iPhone 2UCSB researchers identify the mechanisms underlying salt-mediated behaviors in fruit flies 2UCSB researchers identify the mechanisms underlying salt-mediated behaviors in fruit flies 3Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 2011 Asmacure Ltee, a clinical-stage biopharmaceutical ... for the treatment of asthma and other inflammatory diseases, ... chief executive officer.  With a solid foundation established at ... progresses its lead compound, a potential new treatment for ...
... KONG, June 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... plan to release financial results for the fourth quarter and ... 2011, after market close in the US.   ... ET on Monday, June 13, 2011 to discuss its financial ...
Cached Biology Technology:EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:6/14/2013)... World War II soldiers, "The White Cliffs of Dover" ... times. To geographers, the white cliffs mark the point ... scientists, the white cliffs are towering structures made of ... alga known as Emiliania huxleyi . "Ehux" is ... Even though the process by which the alga,s "armor" ...
(Date:6/14/2013)... OttawaJune 14, 2013Here,s a good reason to pay ... has published a paper from Ottawa researchers today, ... in the fight against cancer. The technique predicts ... cancer-killing, oncolytic viruses to overcome the natural defences ... infection. , "Oncolytic viruses are special in ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Using math to kill cancer cells 22013 World Cultural Council awards 22013 World Cultural Council awards 3
... major new review of scientific knowledge on kava a ... with calming effects has left unsolved the mystery of ... in the United States, Europe, and other Western cultures sometimes ... Chemical Research in Toxicology . Line Olsen and colleagues ...
... release is available in German and Spanish ... in Chile pose a higher threat to its neighbour, Argentina, ... University of Concepcin in Chile and the Helmholtz Centre for ... In particular, 22 non-native species which occur in Chile on ...
... , This release is available in German ... protects them against diseases. The early detection of pathogens and ... work as a protective shield. However, the pathogens that cause ... suppress the natural cell wall reaction in plants. "One particularly ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3TUM researchers discover a new switch in resistance to plant diseases 2
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Choriongonadotropin (human, hCG)...
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
... Running Buffer was designed to meet the ... todays sequencing labs. As a primary manufacturer ... gel-based sequencing community Sigma has the know ... your buffer needs. Scientists at Sigma have ...
Biology Products: